SeleXel Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

SeleXel General Information


Developer of biotech solutions designed to treat invasive and metastatic cancers. The company develops a portfolio of molecules based on RNA interference technology that inhibits very specifically the production of a protein playing a key role in the development or progression of cancer, enabling healthcare professionals to restore the ability of the immune system to eliminate the tumor.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Drug Discovery
Other Industries
Corporate Office
  • 85 B Rue Louise Aglae Crette
  • 94400 Paris
  • France

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SeleXel Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 00.000 Completed Out of Business
3. Angel (individual) 14-Dec-2017 00000 00.000 00.000 Completed Generating Revenue
2. Angel (individual) 27-Jan-2014 $654K $654K 00.000 Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view SeleXel’s complete valuation and funding history, request access »

SeleXel Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 000 0000.00 0000.00 00 0000.00 0.000
Ordinary 000 0000.00 0000.00 00 0000.00 0.000
Ordinary 000 0000.00 0000.00 00 0000.00 0.000
Ordinary 796 $472.82 $472.82 1x $472.82 5.12%
Ordinary 430 $443.27 $443.27 1x $443.27 2.77%
To view SeleXel’s complete cap table history, request access »

SeleXel Patents

SeleXel Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210292755-A1 Novel double-stranded oligonucleotides for the treatment of cancer Inactive 27-Oct-2016 000000000
US-20190336520-A1 Use of a sirna for treating cancer Inactive 27-Oct-2016 0000000000
EP-3532086-A1 Novel bispecific double-stranded oligonucleotide for treating cancer Inactive 27-Oct-2016 000000000
EP-3532088-A1 Use of a sirna for treating cancer Inactive 27-Oct-2016 0000000000
CA-3041624-A1 Use of a sirna for treating cancer Inactive 27-Oct-2016 A61K31/713
To view SeleXel’s complete patent history, request access »

SeleXel FAQs

  • When was SeleXel founded?

    SeleXel was founded in 2006.

  • Who is the founder of SeleXel?

    Pierre Attali MD, Florence Cabon Ph.D, and Pierre Attali MD are the founders of SeleXel.

  • Where is SeleXel headquartered?

    SeleXel is headquartered in Paris, France.

  • What industry is SeleXel in?

    SeleXel’s primary industry is Drug Discovery.

  • Is SeleXel a private or public company?

    SeleXel is a Private company.

  • What is SeleXel’s current revenue?

    The current revenue for SeleXel is 00000.

  • How much funding has SeleXel raised over time?

    SeleXel has raised $1.12M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »